47 356

Cited 0 times in

Cytosine deaminase-producing human mesenchymal stem cells mediate an antitumor effect in a mouse xenograft model.

Authors
You, MH; Kim, WJ; Shim, W; Lee, SR; Lee, G; Choi, S; Kim, DY; Kim, YM; Kim, H; Han, SU
Citation
Journal of gastroenterology and hepatology, 24(8):1393-1400, 2009
Journal Title
Journal of gastroenterology and hepatology
ISSN
0815-93191440-1746
Abstract
BACKGROUND AND AIM: Stem cell transplantation offers potential gene therapy for brain tumors. However, this approach has received little attention as a treatment for gastrointestinal tumors. In the present study, we explored the possibility of human bone marrow-derived mesenchymal stem cells (hMSC) producing cytosine deaminase (CD), followed by systemic 5-fluorocytosine (5-FC) administration, showing an antitumor effect on a mouse gastric cancer xenograft.



METHODS: We first explored the ability of hMSC, coated with fluorescent dye, to migrate to human gastric cancer MKN45 cells in vitro and in vivo. We then used hMSC in which a gene expressed the prodrug-activating enzyme CD, which can convert the prodrug 5-FC into the cytotoxic agent 5-fluorouracil (5-FU), and further investigated the potential of these cells to deliver the CD gene and to reduce tumor growth in nude mice. The migratory capacity of hMSC was confirmed by an in vitro migration assay, as well as in an in vivo model of nude mice bearing subcutaneous tumors of MKN45 cells when hMSC were injected.



RESULTS: The migration ability of hMSC towards MKN45 cells was confirmed by migration assay. Effective conversion of 5-FC to 5-FU by hMSC transfected with the CD gene (CD-hMSC) showed therapeutic anticancer potential in a MKN45 cell co-culture system, as confirmed by thin layer chromatography. Nude mice bearing MKN45 tumors were intravenously injected with CD-hMSC, followed by systemic 5-FC treatment (500 mg/kg/day) for 7 days. Tumor volumes and weights of mice injected with CD-hMSC decreased significantly after treatment with 5-FC. However, the 5-FC-treated group without CD-hMSC injection showed neither a decrease in tumor volume nor bodyweight loss.



CONCLUSION: The CD-hMSC system showed anticancer therapeutic potential, and minimized the side-effects of 5-FU.
MeSH terms
AnimalsAntimetabolites, Antineoplastic/administration & dosage*Antimetabolites, Antineoplastic/metabolismCarbocyaninesCell Line, TumorCell MovementCytosine Deaminase/biosynthesis*Cytosine Deaminase/geneticsDose-Response Relationship, DrugEscherichia coli Proteins/biosynthesis*Escherichia coli Proteins/geneticsFemaleFlucytosine/administration & dosage*Flucytosine/metabolismFluorescent DyesFluorouracil/administration & dosage*Fluorouracil/metabolismHumansInjections, IntraperitonealMesenchymal Stem Cell Transplantation*Mesenchymal Stem Cells/enzymology*MiceMice, NudeMicroscopy, FluorescenceNIH 3T3 CellsProdrugs/administration & dosage*Prodrugs/metabolismStomach Neoplasms/enzymologyStomach Neoplasms/geneticsStomach Neoplasms/pathologyStomach Neoplasms/therapy*Time FactorsTransfectionXenograft Model Antitumor Assays
DOI
10.1111/j.1440-1746.2009.05862.x
PMID
19486256
Appears in Collections:
Journal Papers > School of Medicine / Graduate School of Medicine > Surgery
Journal Papers > School of Medicine / Graduate School of Medicine > Gastroenterology
AJOU Authors
이, 상림이, 광재한, 상욱
Export
RIS (EndNote)
XLS (Excel)
XML

qrcode

해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse